Cargando…
Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and c...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112682/ https://www.ncbi.nlm.nih.gov/pubmed/30396425 http://dx.doi.org/10.1016/j.cimid.2018.09.009 |
_version_ | 1783513521508581376 |
---|---|
author | Lafaye, Pierre Li, Tengfei |
author_facet | Lafaye, Pierre Li, Tengfei |
author_sort | Lafaye, Pierre |
collection | PubMed |
description | Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases. |
format | Online Article Text |
id | pubmed-7112682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71126822020-04-02 Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases Lafaye, Pierre Li, Tengfei Comp Immunol Microbiol Infect Dis Article Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases. Elsevier Ltd. 2018-10 2018-09-25 /pmc/articles/PMC7112682/ /pubmed/30396425 http://dx.doi.org/10.1016/j.cimid.2018.09.009 Text en © 2018 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Lafaye, Pierre Li, Tengfei Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title_full | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title_fullStr | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title_full_unstemmed | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title_short | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
title_sort | use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112682/ https://www.ncbi.nlm.nih.gov/pubmed/30396425 http://dx.doi.org/10.1016/j.cimid.2018.09.009 |
work_keys_str_mv | AT lafayepierre useofcamelsingledomainantibodiesforthediagnosisandtreatmentofzoonoticdiseases AT litengfei useofcamelsingledomainantibodiesforthediagnosisandtreatmentofzoonoticdiseases |